Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2008-05-27
2008-05-27
Parkin, Jeffrey S. (Department: 1648)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C424S188100, C424S208100
Reexamination Certificate
active
07378515
ABSTRACT:
The present invention relates to synthetic gag and gagpol genes optimized for high level expression via codon optimization and the uses thereof for the efficient generation of vector particles. The invention further relates to the generation of packaging cells and vaccines based on the synthetic gag and gagpol genes.
REFERENCES:
patent: WO 98/34640 (1998-08-01), None
patent: WO 00/15819 (2000-03-01), None
patent: WO 00/39304 (2000-07-01), None
Ellington, A., and J. M. Cherry, 1997, Characteristics of Amino Acids, Curr. Prot. Molec. Biol. A.1C.1-A.1C.12.
2006 Instructions to Authors, 2006, J. Virol. 80(1):15-16, (1-17).
Murphy, F. A., 1996, Virus Taxonomy, in Fields Virology, Third Edition, Fields, B. N., et al., eds., Lippincott-Raven Publishers, Philadelphia, pp. 40-41.
Xiang, G., et al., 2003, Translational recoding signals between gag and pol in diverse LTR retrotransposons, RNA 9(12):1422-1430, abstract provided.
Graf et al., “Concerted action of multiple cis-acting sequences is required for rev dependence of late human immunodeficiency type 1 gene expression,”J. Virol., 74:10822-10826, 2000.
Haas et al., “Codon usage limitation in the expression of HIV-1 envelope glycoprotein,”Curr. Biol., 6:315-324, 1996.
Kotsopoulou et al., “A rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene,”J. Virol., 74:4839-4852, 2000.
Luban and Goff, “Mutational analysis of cis-acting packaging signals in human immunodeficiency virus type 1 RNA,”J. Virol., 68:3784-3793, 1994.
Qiu et al., “Evaluation of novel human immunodeficiency virus type 1 gag DNA vaccines for protein expression in mammalian cells and induction of immune responses,”J. Virol., 73:9145-9152, 1999.
Schneider et al., “Inactivation of the human immunodeficiency virus type inhibitory elements allows rev-independent expression of gag and gag/protease and particle formation,”J. Virol., 71:4892-4903, 1997.
Schwartz et al., “Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in rev-independent gag expression,”J. Virol., 66:7176-7182, 1992.
Bieler Kurt
Deml Ludwig
Graf Markus
Wagner Ralf
Fulbright & Jaworski LLP
Geneart AG
Parkin Jeffrey S.
LandOfFree
Synthetic gagpol genes and their uses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthetic gagpol genes and their uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthetic gagpol genes and their uses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2793486